Fosun Health Hosts First International Oncology Treatment Forum in Foshan; International Oncology Alliance Officially Established
FOSHAN, China, Sept. 20, 2026 /PRNewswire/ -- The first International Oncology Treatment Forum, hosted by Fosun Health, was held in Foshan, Guangdong Province, China. Oncology experts from multiple countries and regions participated in the...
Jiahui Health Highlights China's Growing Role in Global Medical Tourism at WTO Public Forum 2026
GENEVA, Sept. 18, 2026 /PRNewswire/ -- China is seeing growing momentum in inbound medical tourism, driven by expanding access to innovative therapies, visa facilitation and the development of internationally oriented healthcare services, Dr. John...
T-MAXIMUM B7-H3-Targeted Allogeneic CAR-T Therapy MT027 Receives FDA Fast Track Designation, Accelerating Global Development for Intracranial Solid Tumors
MT027 has previously been granted FDA Orphan Drug Designation and has entered Phase II clinical development in recurrent glioblastoma BEIJING, Aug. 31, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL Inc. ("T-MAXIMUM") today announced that its...
Fosun International Holds 2026 Interim Results Presentation: Unlocking Core Pathways, Accelerating Growth in Industries where we Excel
HONG KONG, Aug. 31, 2026 /PRNewswire/ -- On the morning of 28 August, Fosun International held its 2026 interim results presentation in Hong Kong. This marks Fosun's return to Hong Kong to hold a results presentation for the first time in six years....
IASO Biotechnology Announces Acquisition of Singapore-Based Cell Therapy Company MediSix Therapeutics
NANJING, China, SHANGHAI and SINGAPORE, Aug. 13, 2026 /PRNewswire/ -- IASO Biotechnology ("IASO Bio") today announced the completion of its acquisition of MediSix Therapeutics ("MediSix"), a Singapore-based immune cell engineering and cell therapy...
RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias
The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo...
From Patient to Storyteller: Dale Returns to Shanghai After CAR-T Recovery, Sharing a Journey of Hope
SHANGHAI, Aug. 5, 2026 /PRNewswire/ -- After overcoming stage 4B lymphoma through CAR-T therapy, New Zealand patient Dale has returned to Shanghai—not as a patient seeking treatment, but as a survivor sharing his story. Recently, Dale came back to...
Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
CRANBURY, N.J. and SUZHOU,China, Aug. 5, 2026 /PRNewswire/ -- Recently, Porton Advanced Solutions Ltd. ("Porton Advanced") has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Administration (NMPA)....
NueCell Bio Announces its Launch as a New Translational Partner for Cell Therapies with Unique Expertise to Accelerate Treatments from Discovery into GMP Manufacturing
SAN DIEGO, Aug. 5, 2026 /PRNewswire/ -- NueCell Bio, a newly established cell therapy science and development services company that utilizes proprietary modular translational development solutions focused on advancing modern cell therapies from...
CellOrigin Unveils Two Novel Solid-Tumor Cell Therapy Candidates at ASCO 2026, Partners with Walvax for In Vivo CAR Clinical Trial
HANGZHOU, China, July 31, 2026 /PRNewswire/ -- CellOrigin, a biotechnology company focused on next-generation in vivo and in vitro cell therapy technologies, has announced two major progresses in both research and strategic partnership. At the 2026...